Reuters logo
BRIEF-PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL
September 20, 2017 / 7:47 PM / a month ago

BRIEF-PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL

Sept 20 (Reuters) - PhaseRx Inc:

* PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL for the treatment of Argininosuccinate Lyase Deficiency Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below